Stock CVKD CADRENAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-22 EDT 		5-day change 1st Jan Change
0.4127 USD -1.74% Intraday chart for Cadrenal Therapeutics, Inc. -6.92% -44.22%
05-09 Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-09 Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
PR
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
PR
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
CI
Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin
DJ
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
PR
Cadrenal Therapeutics Files $100 Million Mixed Shelf; Shares Fall
MT
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CADRENAL THERAPEUTICS TO PARTICIPATE AT TECHNOLOGY AND HEART FAILURE THERAPEUTICS CONFERENCE
AQ
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
PR
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
PR
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer
CI
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
PR
Certain Warrants of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.
CI
Certain Common Stock of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.
CI
Certain Stock Options of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.
CI
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
PR
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
PR
Noble Capital Starts Cadrenal Therapeutics With Outperform Rating, $4 Price Target
MT
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVKD Stock
  4. News Cadrenal Therapeutics, Inc.